|
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL). |
| |
|
Consulting or Advisory Role - A2 Biotherapeutics; Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Caribou Biosciences; Celgene; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Miltenyi Biotec; Novartis; Sana Biotechnology; Takeda; Takeda; Umoja Biopharma; Umoja Biopharma |
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst) |
Travel, Accommodations, Expenses - A2 Biotherapeutics; Kite, a Gilead company |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Abbvie; BeiGene; Genentech; Incyte; MorphoSys; Pharmacyclics |
Consulting or Advisory Role - Abbvie; BeiGene; Genentech; Incyte; MorphoSys |
Speakers' Bureau - Abbvie; BeiGene; Genentech; Incyte; MorphoSys |
Research Funding - Abbvie; AstraZeneca; Atara Biotherapeutics; BeiGene; BMSi; Celgene; Genentech; Gilead Sciences; Incyte; Juno Therapeutics; Kite, a Gilead Company; MorphoSys; Pharmacyclics |
| |
|
Honoraria - Curio Science; Kyowa Hakko Kirin; OncView; Physicans' Education Resource; Seagen; Targeted Oncology |
Consulting or Advisory Role - ADC Therapeutics; Alexion Pharmaceuticals; Aurobindo; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Debiopharm Group; Epizyme; Fosun Kite; Genentech; Genmab; Gilead Sciences; Innovent Biologics; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; MEI Pharma; MorphoSys; Novartis; Pfizer; Pharmacyclics; Seagen; Secura Bio; SERVIER; TG Therapeutics; Zodiac Pharma |
Speakers' Bureau - Abbvie/Genentech; Acrotech Biopharma; AstraZeneca; Bayer; BeiGene; BeiGene; Celgene; Gilead Sciences; Kite, a Gilead company; Kyowa Hakko Kirin; Pharmacyclics/Janssen; Seagen; Verastem |
Research Funding - Celgene; Genentech/Abbvie; Incyte; Kite, a Gilead company; Millennium; Pharmacyclics/Janssen; Portola Pharmaceuticals; Seagen |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Incyte |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - ADC Therapeutics; Kite, a Gilead company |
| |
|
|
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem |
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead |
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda |
| |
|
Consulting or Advisory Role - ADC Therapeutics; Curio Science; Epizyme; Gilead Sciences; Kite/Gilead; Legend Biotech; Nektar; Novartis; Syncopation Life Sciences |
Research Funding - Kite, a Gilead company (Inst) |
| |
|
Stock and Other Ownership Interests - NexImmune |
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Cidara Therapeutics; Incyte; Kite/Gilead; Medigene; Merck; MolMed; Nektar; NexImmune; Novartis; Omeros; Servier/Pfizer; Vor Biopharma |
Research Funding - Incyte (Inst); Kite, a Gilead company (Inst); Miltenyi Biotec (Inst); Nektar (Inst); Novartis (Inst) |
| |
|
Honoraria - fosun Kite Biotechnology; Janssen |
Consulting or Advisory Role - Adaptive Biotechnologies; Allogene Therapeutics; Caribou Biosciences; Janssen; Kite, a Gilead company |
Research Funding - Adaptive Biotechnologies; Adicet Bio; Alimera Sciences; Kite, a Gilead company; Novartis; Pharmacyclics; Precision Biosciences; Roche/Genentech |
Patents, Royalties, Other Intellectual Property - Patent held with Pharmacyclics supporting Ibrutinib for cGVHD (no royalty claim) |
| |
|
No Relationships to Disclose |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
| |
|
Employment - Allogene Therapeutics |
Stock and Other Ownership Interests - Allogene Therapeutics |
Patents, Royalties, Other Intellectual Property - Allogene Therapeutics |
| |
|
Stock and Other Ownership Interests - Longbow Immunotherapy |
Honoraria - MJH Life Sciences; Peerview |
Consulting or Advisory Role - Adicet Bio; Alimera Sciences; Astellas Pharma; Athenex; Bluebird Bio; Bristol-Myers Squibb; Caribou Biosciences; Chimagen Biosciences; Fosun Kite; Gilead Sciences; ImmunoACT; Incyte; Janssen medical Affairs; Kite, a Gilead company; Morphosys; Orna Therapeutics; Sana Biotechnology; Sellas Life Sciences; Takeda |
Research Funding - Adicet Bio; Alimera Sciences; Bristol-Myers Squibb; Gilead Sciences; Kite, a Gilead company; Precision Biosciences |
Patents, Royalties, Other Intellectual Property - Patents related to cellular therapy |